KYNB Reports $1.3M Q4 Rev, $58.2M Net Loss, $109.4M Cash Runway to 2028, Launches Phase 3 Roxadustat Protocol Submission
Kyntra Bio, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $6.90
-2.3% since the alert
$7.00 → $6.84
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS